GoldenGolden
Foresite Capital

Foresite Capital

A private equity firm in California that provides catalytic capital to transformative healthcare companies at all stages

Foresite Capital is a private equity firm in California that provides catalytic capital to transformative healthcare companies at all stages. Founded 2011 in San Francisco, California, United States by Jim Tananbaum, this private equity firm invests in private equity, early stage ventures and late stage ventures. Its portfolio companies include Genapsys, Aimmune Therapeutics, Generation Bio, Element Biosciences, and Kinnate Biopharma. As of February 2020, Foresite Capital has made 66 investments. Their most recent investment was on Jan 11, 2020, when Generation Bio raised $110M. Foresite Capital has had 27 exits. Foresite Capital's most notable exits include Aimmune Therapeutics, Twist Bioscience, and Alector. The company has raised 4 funds, their latest being Foresite Capital Fund IV. This fund was announced on May 3, 2018 and raised a total of $668M. The company prefers to invest in the healthcare, therapeutics, devices, diagnostics and services sectors.

Timeline

February 23, 2021
Foresite Capital banks $969 million in its fifth and biggest raise yet to invest in companies solving some of the biggest inefficiencies in today's healthcare system.
2011
Founded

Funded Companies

Company
Description
Industry
Website
Location
Twist Bioscience

A DNA synthesis company using a next-generation silicon-based technology platform.

Intellia Therapeutics is a biotechnology company founded in 2014, based in Cambridge, MA that develops biopharmaceuticals using CRISPR-Cas9 gene editing technology.

Decibel Therapeutics conducts inner ear research to deliver medicines for hearing and balance.

A biotechnology company offering a genomics platform supporting scientific research into life sciences such as oncology, immunology, and neuroscience.

A therapeutics company founded in 2016 working in drug discovery and development using fungi. LifeMine uses genomics approaches to search for biosynthetic genes in eukaryotic microbes for the discovery of naturally inspired drugs to treat previously untreatable and significant chronic diseases.

Sage Therapeutics is a biopharmaceutical company founded by Douglas Covey and Steven Paul in 2010 and headquartered in Cambridge, Massachusetts focused on the discovery and development of medicines to address central nervous system disorders.

A gene editing technology company founded in 2015 and based in Boulder, CO, USA.

Relay Therapeutics is a Cambridge, Massachusetts-based developer of an allosteric drug-discover platform that is intended to apply computational techniques to protein motion.

Juvenescence is a venture capital and development company focused on developing therapies targeting aging, age-related disease and regeneration.

Turning Point Therapeutics, Inc. is a clinical-stage drug design company that specializes in the discovery and development of targeted cancer therapies

Solid Biosciences is a Cambridge, Massachusetts-based biotechnology company focused on solving Duchenne muscular dystrophy.

An independent vaccine platform in California that focuses on delivering best-in-class conjugate vaccines and complex antigen-based vaccines to prevent deadly infectious diseases.

Orchard Therapeutics is a biotechnology company developing gene therapies for rare diseases.

Cue Health is a San Diego-based medical device company working to track health information at the molecular level.

ALX Oncology is a Burlingame, California-based biotechnology company working on pre-clinical stage immuno-oncology therapies.

Replimune Group, Inc. is a clinical-stage biotechnology company.

Maze Therapeutics is a San Francisco-based biotechnology company developing genetics-based therapeutics

35 Results
Results per page:
Page 1 of 2

Associated investment funds

Investment Fund
Total offering (USD)
Total sold (USD)
Location
Date signed
Foresite Capital Fund V, L.P.
705,000,000
November 2019
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Dorothy Margolskee

Managing Director

Brett Zbar

Managing Director

Jim Tananbaum

Founding CEO

Linda Schaffer

Director

Molly He

Venture Partner

Vikram Bajaj

Managing Director

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Pharvaris

Element Biosciences

Genapsys

Generation Bio

HealthVerity

Inscripta, Inc

Insitro

Kinnate Biopharma

ORIC Pharmaceuticals

News

Title
Author
Date
Publisher
Description
Annalee Armstrong
April 13, 2021
FierceBiotech
Theseus Pharmaceuticals, led by a team of ex-Ariad executives, will target treatment-resistant cancers after emerging from stealth mode with $100 million in Series B funding.
FinSMEs
April 13, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Theseus Pharmaceuticals
April 13, 2021
www.prnewswire.com:443
/PRNewswire/ -- Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase...
Heather Landi
April 5, 2021
FierceHealthcare
Cleo Health hauled in $40 million to scale up its family benefits platform for working parents and families, BrightInsight banked $101 million to grow its digital health platform for biopharma and medtech companies and more funding news in March.
Amirah Al Idrus
February 23, 2021
FierceBiotech
Foresite Capital banked $969 million in its fifth and biggest raise yet to invest in companies solving some of the biggest inefficiencies in today's healthcare system. The capital will be split into two funds: About $775 million, or 80%, will go into a core fund, while the remaining $194 million will become what the firm calls an opportunity fund.
Amirah Al Idrus
February 19, 2021
FierceBiotech
The SPAC attack is not abating. This week alone, Foresite Capital's second special purpose acquisition company raised $175 million in its IPO, while two other biotech SPACs--European Biotech Acquisition and Frontier Acquisition--filed to raise a total of $300 million in their Nasdaq debuts.
AlleyWatch
June 13, 2020
AlleyWatch
The Pulse of New York Tech
May 27, 2020
BioSpace
Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace
November 20, 2019
WebWire
GenapSys Inc. announced today that it has completed a $90 million funding round, led by Foresite Capital to commercialize the smallest and most affordable highly accurate sequencer ever developed. This latest investment round brings the company's total funding to $166 million to date. Now available for purchase, the device uses first-of-its-kind technology to deliver results at a fraction of the cost of legacy technologies, while still delivering highly-accurate results. The new capita...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.